Dengue Clinical Trial
Official title:
Effects of a Serious Game on Knowledge, Attitude and Practice in Vector Control and Dengue Prevention Among Adults in Primary Care: A Randomized Controlled Trial
Verified date | March 2022 |
Source | SingHealth Polyclinics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Dengue can be mitigated by both vector control and vaccination. Serious games in healthcare can be used to raise the community awareness of vector control in dengue prevention in a simulated interactive learning environment, by motivating serious game participants to optimise their own performance and influence their behaviour. The results show a specially designed serious game can better engage local residents by raising their awareness in vector control and proactiveness in dengue prevention. At least 8 out of 10 participants were willing to be vaccinated against dengue if they knew of the availability of a safe and effective vaccine.
Status | Completed |
Enrollment | 400 |
Est. completion date | September 17, 2021 |
Est. primary completion date | September 17, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 60 Years |
Eligibility | Inclusion Criteria: - Adult who is visiting Sengkang Polyclinic. - Able to understand English. - Has a mobile phone which was compatible with the serious game and willing to download and attempt the serious game. - Able to complete questionnaires on the online secured platform, Form.sg. Exclusion Criteria: - Adult who is not able to use a mobile phone due to physical or cognitive impairments. |
Country | Name | City | State |
---|---|---|---|
Singapore | SingHealth Polyclinics - Sengkang | Singapore |
Lead Sponsor | Collaborator |
---|---|
SingHealth Polyclinics |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of knowledge, attitude and practice (KAP) assessment score on dengue fever prevention | This outcome is measured via a participant-administered questionnaire which was used and validated in previous regional studies. It is divided into 3 sections: (1) knowledge (16 items), (2) attitude (15 items), (3) practice (15 items) in preventing dengue.
The minimum and maximum values of this questionnaire are 0 and 46 respectively. A higher score indicates a better outcome. |
Change from baseline KAP score at 2 weeks (or within 2 weeks after completion of intervention) | |
Secondary | Change of interest to vaccinate against Dengue | This outcome is measured via a participant-administered questionnaire. It consists of 1 section: (1) interest to vaccinate against Dengue (1 item).
A higher proportion of participants indicating interest to vaccinate against Dengue indicates a better outcome. |
Change from baseline Dengue vaccination interest at 2 weeks (or within 2 weeks after completion of intervention) | |
Secondary | System Usability Scale (SUS) score of serious game | This outcome is measured via a participant-administered questionnaire. It is modified from the validated SUS template to evaluate the usability of this serious game. The SUS has 10 statements, and a 5-point Likert scale is used to indicate the participant's agreement with the statements.
The response of each participants is collated and a standardized formula is applied to calculate the final SUS score. A score above 68 is above average and scores below 68 is below average in terms of system usability. A score of less than 68 indicates that the participants may have less than average user experience with the serious game. |
At 2 weeks from start of study (or within 2 weeks after completion of intervention by the serious game group) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321264 -
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
|
N/A | |
Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01391819 -
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
|
N/A | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02833584 -
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
|
N/A | |
Completed |
NCT02433652 -
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
|
Phase 1 | |
Enrolling by invitation |
NCT02016027 -
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Recruiting |
NCT00377754 -
Prospective Study of Infant Dengue
|
N/A | |
Recruiting |
NCT05919277 -
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
|
||
Recruiting |
NCT04582474 -
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
|
N/A | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT03803618 -
Dengue Effectiveness Study in the Philippines
|
||
Active, not recruiting |
NCT05967455 -
Homologous Re-infection With Dengue 1 or Dengue 3
|
Phase 1 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Recruiting |
NCT02606019 -
The Use of Biomarkers in Predicting Dengue Outcome
|
N/A | |
Completed |
NCT02372175 -
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
|
Phase 1 | |
Active, not recruiting |
NCT01696422 -
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
|
Phase 2 | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT00375726 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
|
Phase 1 |